Breakthroughs in hepatitis C research: from discovery to cure (original) (raw)

• Maasoumy, B. & Wedemeyer, H. Natural history of acute and chronic hepatitis C. Best. Pr. Res. Clin. Gastroenterol. 26, 401–412 (2012).
  Article Google Scholar
• World Health Organization. Global Hepatitis Report. WHO https://apps.who.int/iris/bitstream/handle/10665/255016/9789?sequence=1 (2017).
• Alter, H. J. et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N. Engl. J. Med. 321, 1494–1500 (1989).
  Article CAS PubMed Google Scholar
• Stramer, S. L. et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N. Engl. J. Med. 351, 760–768 (2004).
  Article CAS PubMed Google Scholar
• Pawlotsky, J.-M. et al. EASL recommendations on treatment of hepatitis C: final update of the series. J. Hepatol. 73, 1170–1218 (2020).
  Article Google Scholar
• World Health Organization. Combating Hepatitis B and C to Reach Elimination by 2030. WHO https://apps.who.int/iris/handle/10665/206453 (2016).
• Manns, M. P. et al. Hepatitis C virus infection. Nat. Rev. Dis. Primers 3, 17006 (2017).
  Article PubMed Google Scholar
• Alter, H. J. et al. Posttransfusion hepatitis after exclusion of commercial and hepatitis-B antigen-positive donors. Ann. Intern. Med. 77, 691–699 (1972).
  Article CAS PubMed Google Scholar
• Prince, A. M. et al. Long-incubation post-transfusion hepatitis without serological evidence of exposure to hepatitis-B virus. Lancet 2, 241–246 (1974).
  Article CAS PubMed Google Scholar
• Alter, H. J. et al. Clinical and serological analysis of transfusion-associated hepatitis. Lancet 2, 838–841 (1975).
  Article CAS PubMed Google Scholar
• Feinstone, S. M., Kapikian, A. Z., Purcell, R. H., Alter, H. J. & Holland, P. V. Transfusion-associated hepatitis not due to viral hepatitis type A or B. N. Engl. J. Med. 292, 767–770 (1975).
  Article CAS PubMed Google Scholar
• Alter, H. J., Purcell, R. H., Holland, P. V. & Popper, H. Transmissible agent in non-A, non-B hepatitis. Lancet 1, 459–463 (1978).
  Article CAS PubMed Google Scholar
• Tabor, E. et al. Transmission of non-A, non-B hepatitis from man to chimpanzee. Lancet 1, 463–466 (1978).
  Article CAS PubMed Google Scholar
• Bradley, D. W. et al. Persistent non-A, non-B hepatitis in experimentally infected chimpanzees. J. Infect. Dis. 143, 210–218 (1981).
  Article CAS PubMed Google Scholar
• Hruby, M. A. & Schauf, V. Transfusion-related short-incubation hepatitis in hemophilic patients. JAMA 240, 1355–1357 (1978).
  Article CAS PubMed Google Scholar
• Wyke, R. J. et al. Transmission of non-A non-B hepatitis to chimpanzees by factor-IX concentrates after fatal complications in patients with chronic liver disease. Lancet 1, 520–524 (1979).
  Article CAS PubMed Google Scholar
• Yoshizawa, H. et al. Viruslike particles in a plasma fraction (fibrinogen) and in the circulation of apparently healthy blood donors capable of inducing non-A/non-B hepatitis in humans and chimpanzees. Gastroenterology 79, 512–520 (1980).
  Article CAS PubMed Google Scholar
• Colombo, M. et al. Transmission of non-A, non-B hepatitis by heat-treated factor VIII concentrate. Lancet 2, 1–4 (1985).
  Article CAS PubMed Google Scholar
• Lane, R. Non-A, non-b hepatitis from intravenous immunoglobulin. Lancet 322, 974–975 (1983).
  Article Google Scholar
• Lever, A. M., Webster, A. D., Brown, D. & Thomas, H. C. Non-A, non-B hepatitis occurring in agammaglobulinaemic patients after intravenous immunoglobulin. Lancet 2, 1062–1064 (1984).
  Article CAS PubMed Google Scholar
• Bradley, D. W. et al. Experimental infection of chimpanzees with antihemophilic (factor VIII) materials: recovery of virus-like particles associated with non-A, non-B hepatitis. J. Med. Virol. 3, 253–269 (1979).
  Article CAS PubMed Google Scholar
• Mosley, J. W., Redeker, A. G., Feinstone, S. M. & Purcell, R. H. Mutliple hepatitis viruses in multiple attacks of acute viral hepatitis. N. Engl. J. Med. 296, 75–78 (1977).
  Article CAS PubMed Google Scholar
• Norkrans, G., Frösner, G., Hermodsson, S. & Iwarson, S. Multiple hepatitis attacks in drug addicts. JAMA 243, 1056–1058 (1980).
  Article CAS PubMed Google Scholar
• Galbraith, R. M., Eddleston, A. L., Portmann, B., Williams, R. & Gower, P. E. Chronic liver disease developing after outbreak of HBsAG-negative hepatitis in haemodialysis unit. Lancet 2, 886–890 (1975).
  Article CAS PubMed Google Scholar
• Rakela, J. & Redeker, A. G. Chronic liver disease after acute non-A, non-B viral hepatitis. Gastroenterology 77, 1200–1202 (1979).
  Article CAS PubMed Google Scholar
• Tabor, E., Seeff, L. B. & Gerety, R. J. Chronic non-A, non-B hepatitis carrier state: transmissible agent documented in one patient over a six-year period. N. Engl. J. Med. 303, 140–143 (1980).
  Article CAS PubMed Google Scholar
• Koretz, R. L., Stone, O. & Gitnick, G. L. The long-term course of non-A, non-B post-transfusion hepatitis. Gastroenterology 79, 893–898 (1980).
  Article CAS PubMed Google Scholar
• Realdi, G. et al. Long-term follow-up of acute and chronic non-A, non-B post-transfusion hepatitis: evidence of progression to liver cirrhosis. Gut 23, 270–275 (1982).
  Article CAS PubMed PubMed Central Google Scholar
• Kiyosawa, K. et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 12, 671–675 (1990).
  Article CAS PubMed Google Scholar
• Aach, R. D. et al. Serum alanine aminotransferase of donors in relation to the risk of non-A,non-B hepatitis in recipients: the transfusion-transmitted viruses study. N. Engl. J. Med. 304, 989–994 (1981).
  Article CAS PubMed Google Scholar
• Bradley, D. W. et al. Posttransfusion non-A, non-B hepatitis: physicochemical properties of two distinct agents. J. Infect. Dis. 148, 254–265 (1983).
  Article CAS PubMed Google Scholar
• Bradley, D. W. et al. Posttransfusion non-A, non-B hepatitis in chimpanzees. Physicochemical evidence that the tubule-forming agent is a small, enveloped virus. Gastroenterology 88, 773–779 (1985).
  Article CAS PubMed Google Scholar
• Choo, Q. L. et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244, 359–362 (1989).
  Article CAS PubMed Google Scholar
• Koziol, D. E. et al. Antibody to hepatitis B core antigen as a paradoxical marker for non-A, non-B hepatitis agents in donated blood. Ann. Intern. Med. 104, 488–495 (1986).
  Article CAS PubMed Google Scholar
• Alter, H. J. The road not taken or how I learned to love the liver: a personal perspective on hepatitis history. Hepatology 59, 4–12 (2014).
  Article PubMed Google Scholar
• Kuo, G. et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 244, 362–364 (1989).
  Article CAS PubMed Google Scholar
• Roggendorf, M. et al. Antibodies to hepatitis C virus. Lancet 2, 324–325 (1989).
  Article CAS PubMed Google Scholar
• Esteban, J. I. et al. Hepatitis C virus antibodies among risk groups in Spain. Lancet 2, 294–297 (1989).
  Article CAS PubMed Google Scholar
• Colombo, M. et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 2, 1006–1008 (1989).
  Article CAS PubMed Google Scholar
• Bruix, J. et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 2, 1004–1006 (1989).
  Article CAS PubMed Google Scholar
• Polaris, O. H. C. V. C. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol. Hepatol. 2, 161–176 (2017).
  Article Google Scholar
• Esteban, J. I. et al. Evaluation of antibodies to hepatitis C virus in a study of transfusion-associated hepatitis. N. Engl. J. Med. 323, 1107–1112 (1990).
  Article CAS PubMed Google Scholar
• [No authors listed.] Effect of screening for hepatitis C virus antibody and hepatitis B virus core antibody on incidence of post-transfusion hepatitis. Japanese Red Cross Non-A, Non-B Hepatitis Research Group. Lancet 338, 1040–1041 (1991).
  Article Google Scholar
• Aach, R. D. et al. Hepatitis C virus infection in post-transfusion hepatitis. An analysis with first- and second-generation assays. N. Engl. J. Med. 325, 1325–1329 (1991).
  Article CAS PubMed Google Scholar
• Shepard, C. W., Finelli, L. & Alter, M. J. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 5, 558–567 (2005).
  Article PubMed Google Scholar
• Maasoumy, B. et al. Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PLoS ONE 8, e55285 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Thursz, M. & Fontanet, A. HCV transmission in industrialized countries and resource-constrained areas. Nat. Rev. Gastroenterol. Hepatol. 11, 28–35 (2014).
  Article CAS PubMed Google Scholar
• Scullard, G. H. et al. Antiviral treatment of chronic hepatitis B virus infection. I. Changes in viral markers with interferon combined with adenine arabinoside. J. Infect. Dis. 143, 772–783 (1981).
  Article CAS PubMed Google Scholar
• Dusheiko, G. et al. Recombinant leukocyte interferon treatment of chronic hepatitis B. Hepatology 5, 556–560 (1985).
  Article CAS PubMed Google Scholar
• Hoofnagle, J. H. et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N. Engl. J. Med. 315, 1575–1578 (1986).
  Article CAS PubMed Google Scholar
• Di Bisceglie, A. M. et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N. Engl. J. Med. 321, 1506–1510 (1989).
  Article PubMed Google Scholar
• Davis, G. L. et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N. Engl. J. Med. 321, 1501–1506 (1989).
  Article CAS PubMed Google Scholar
• Shindo, M. et al. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann. Intern. Med. 115, 700–704 (1991).
  Article CAS PubMed Google Scholar
• Brillanti, S. et al. Effect of alpha-interferon therapy on hepatitis C viraemia in community-acquired chronic non-A, non-B hepatitis: a quantitative polymerase chain reaction study. J. Med. Virol. 34, 136–141 (1991).
  Article CAS PubMed Google Scholar
• Garson, J. A. et al. Hepatitis C viraemia rebound after ‘successful’ interferon therapy in patients with chronic non-A, non-B hepatitis. J. Med. Virol. 37, 210–214 (1992).
  Article CAS PubMed Google Scholar
• Swain, M. G. et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 139, 1593–1601 (2010).
  Article CAS PubMed Google Scholar
• Manns, M. P. et al. Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin. J. Viral Hepat. 20, 524–529 (2013).
  Article CAS PubMed Google Scholar
• Marcellin, P. et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann. Intern. Med. 127, 875–881 (1997).
  Article CAS PubMed Google Scholar
• Jaeckel, E. et al. Treatment of acute hepatitis C with interferon alfa-2b. N. Engl. J. Med. 345, 1452–1457 (2001).
  Article CAS PubMed Google Scholar
• Omata, M. et al. Resolution of acute hepatitis C after therapy with natural beta interferon. Lancet 338, 914–915 (1991).
  Article CAS PubMed Google Scholar
• Reichard, O., Andersson, J., Schvarcz, R. & Weiland, O. Ribavirin treatment for chronic hepatitis C. Lancet 337, 1058–1061 (1991).
  Article CAS PubMed Google Scholar
• Di Bisceglie, A. M. et al. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 16, 649–654 (1992).
  Article PubMed Google Scholar
• Kakumu, S. et al. A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C. Gastroenterology 105, 507–512 (1993).
  Article CAS PubMed Google Scholar
• Brillanti, S. et al. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 107, 812–817 (1994).
  Article CAS PubMed Google Scholar
• McHutchison, J. G. et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339, 1485–1492 (1998).
  Article CAS PubMed Google Scholar
• Poynard, T. et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352, 1426–1432 (1998).
  Article CAS PubMed Google Scholar
• Reichard, O. et al. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 351, 83–87 (1998).
  Article CAS PubMed Google Scholar
• McHutchison, J. G. et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 123, 1061–1069 (2002).
  Article CAS PubMed Google Scholar
• Wills, R. J., Dennis, S., Spiegel, H. E., Gibson, D. M. & Nadler, P. I. Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection. Clin. Pharmacol. Ther. 35, 722–727 (1984).
  Article CAS PubMed Google Scholar
• Karnam, U. S. & Reddy, K. R. Pegylated interferons. Clin. Liver Dis. 7, 139–148 (2003).
  Article PubMed Google Scholar
• Manns, M. P. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958–965 (2001).
  Article CAS PubMed Google Scholar
• Loomes, D. E. & van Zanten, S. V. Bibliometrics of the top 100 clinical articles in digestive disease. Gastroenterology 144, 673–676.e5 (2013).
  Article PubMed Google Scholar
• Fried, M. W. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347, 975–982 (2002).
  Article CAS PubMed Google Scholar
• Rumi, M. G. et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology 138, 108–115 (2010).
  Article CAS PubMed Google Scholar
• Ascione, A. et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 138, 116–122 (2010).
  Article CAS PubMed Google Scholar
• McHutchison, J. G. et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med. 361, 580–593 (2009).
  Article CAS PubMed Google Scholar
• Manns, M. P., Wedemeyer, H. & Cornberg, M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 55, 1350–1359 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Fried, M. W., Hadziyannis, S. J., Shiffman, M. L., Messinger, D. & Zeuzem, S. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J. Hepatol. 55, 69–75 (2011).
  Article PubMed Google Scholar
• Mangia, A. et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N. Engl. J. Med. 352, 2609–2617 (2005).
  Article CAS PubMed Google Scholar
• Berg, T. et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 130, 1086–1097 (2006).
  Article CAS PubMed Google Scholar
• Thomas, D. L. et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461, 798–801 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Ge, D. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399–401 (2009).
  Article CAS PubMed Google Scholar
• Tanaka, Y. et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41, 1105–1109 (2009).
  Article CAS PubMed Google Scholar
• Matsuura, K., Watanabe, T. & Tanaka, Y. Role of IL28B for chronic hepatitis C treatment toward personalized medicine. J. Gastroenterol. Hepatol. 29, 241–249 (2014).
  Article CAS PubMed Google Scholar
• Yoshio, S. et al. Human blood dendritic cell antigen 3 (BDCA3)+ dendritic cells are a potent producer of interferon-λ in response to hepatitis C virus. Hepatology 57, 1705–1715 (2013).
  Article CAS PubMed Google Scholar
• Romero-Gomez, M., Eslam, M., Ruiz, A. & Maraver, M. Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment. Liver Int. 31, 443–460 (2011).
  Article CAS PubMed Google Scholar
• O’Brien, T. R., Yang, H. I., Groover, S. & Jeng, W. J. Genetic factors that affect spontaneous clearance of hepatitis C or B virus, response to treatment, and disease progression. Gastroenterology 156, 400–417 (2019).
  Article PubMed Google Scholar
• Kato, N. et al. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc. Natl Acad. Sci. USA 87, 9524–9528 (1990).
  Article CAS PubMed PubMed Central Google Scholar
• Choo, Q. L. et al. Genetic organization and diversity of the hepatitis C virus. Proc. Natl Acad. Sci. USA 88, 2451–2455 (1991).
  Article CAS PubMed PubMed Central Google Scholar
• Takamizawa, A. et al. Structure and organization of the hepatitis C virus genome isolated from human carriers. J. Virol. 65, 1105–1113 (1991).
  Article CAS PubMed PubMed Central Google Scholar
• Simmonds, P. et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J. Gen. Virol. 74, 2391–2399 (1993).
  Article CAS PubMed Google Scholar
• Francki, R. I. B., Fauquet, C. M., Knudson, D. L. & Brown, F. Classification and Nomenclature of Viruses. Fifth Report of the International Committee on Taxonomy of Viruses. Virology Division of the International Union of Microbiological Societies (Springer, 1991).
• Lohmann, V. Hepatitis C virus cell culture models: an encomium on basic research paving the road to therapy development. Med. Microbiol. Immunol. 208, 3–24 (2019).
  Article PubMed Google Scholar
• Hijikata, M., Kato, N., Ootsuyama, Y., Nakagawa, M. & Shimotohno, K. Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc. Natl Acad. Sci. USA 88, 5547–5551 (1991).
  Article CAS PubMed PubMed Central Google Scholar
• Grakoui, A., Wychowski, C., Lin, C., Feinstone, S. M. & Rice, C. M. Expression and identification of hepatitis C virus polyprotein cleavage products. J. Virol. 67, 1385–1395 (1993).
  Article CAS PubMed PubMed Central Google Scholar
• Bartenschlager, R., Ahlborn-Laake, L., Mous, J. & Jacobsen, H. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J. Virol. 67, 3835–3844 (1993).
  Article CAS PubMed PubMed Central Google Scholar
• Tomei, L., Failla, C., Santolini, E., De Francesco, R. & La Monica, N. NS3 is a serine protease required for processing of hepatitis C virus polyprotein. J. Virol. 67, 4017–4026 (1993).
  Article CAS PubMed PubMed Central Google Scholar
• Failla, C., Tomei, L. & De Francesco, R. Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins. J. Virol. 68, 3753–3760 (1994).
  Article CAS PubMed PubMed Central Google Scholar
• Lin, C., Thomson, J. A. & Rice, C. M. A central region in the hepatitis C virus NS4A protein allows formation of an active NS3-NS4A serine proteinase complex in vivo and in vitro. J. Virol. 69, 4373–4380 (1995).
  Article CAS PubMed PubMed Central Google Scholar
• Bartenschlager, R., Lohmann, V., Wilkinson, T. & Koch, J. O. Complex formation between the NS3 serine-type proteinase of the hepatitis C virus and NS4A and its importance for polyprotein maturation. J. Virol. 69, 7519–7528 (1995).
  Article CAS PubMed PubMed Central Google Scholar
• Tanji, Y., Hijikata, M., Satoh, S., Kaneko, T. & Shimotohno, K. Hepatitis C virus-encoded nonstructural protein NS4A has versatile functions in viral protein processing. J. Virol. 69, 1575–1581 (1995).
  Article CAS PubMed PubMed Central Google Scholar
• Behrens, S. E., Tomei, L. & De Francesco, R. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J. 15, 12–22 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Pileri, P. et al. Binding of hepatitis C virus to CD81. Science 282, 938–941 (1998).
  Article CAS PubMed Google Scholar
• Evans, M. J. et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446, 801–805 (2007).
  Article CAS PubMed Google Scholar
• Ploss, A. et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457, 882–886 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Scarselli, E. et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 21, 5017–5025 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Agnello, V., Abel, G., Elfahal, M., Knight, G. B. & Zhang, Q. X. Hepatitis C virus and other Flaviviridae viruses enter cells via low density lipoprotein receptor. Proc. Natl Acad. Sci. USA 96, 12766–12771 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Kolykhalov, A. A. et al. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 277, 570–574 (1997).
  Article CAS PubMed Google Scholar
• Yanagi, M., Purcell, R. H., Emerson, S. U. & Bukh, J. Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proc. Natl Acad. Sci. USA 94, 8738–8743 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Lohmann, V. et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285, 110–113 (1999).
  Article CAS PubMed Google Scholar
• Blight, K. J., Kolykhalov, A. A. & Rice, C. M. Efficient Initiation of HCV RNA replication in cell culture. Science 290, 1972–1974 (2000).
  Article CAS PubMed Google Scholar
• Wakita, T. et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11, 791–796 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Lamarre, D. et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426, 186–189 (2003).
  Article CAS PubMed Google Scholar
• Hinrichsen, H. et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 127, 1347–1355 (2004).
  Article CAS PubMed Google Scholar
• Vanwolleghem, T. et al. Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse. Gastroenterology 133, 1144–1155 (2007).
  Article CAS PubMed Google Scholar
• Bacon, B. R. et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 364, 1207–1217 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Poordad, F. et al. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364, 1195–1206 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Sherman, K. E. et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N. Engl. J. Med. 365, 1014–1024 (2011).
  Article CAS PubMed Google Scholar
• Jacobson, I. M. et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364, 2405–2416 (2011).
  Article CAS PubMed Google Scholar
• Zeuzem, S. et al. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 364, 2417–2428 (2011).
  Article CAS PubMed Google Scholar
• Sarrazin, C. et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132, 1767–1777 (2007).
  Article CAS PubMed Google Scholar
• Romano, K. P., Ali, A., Royer, W. E. & Schiffer, C. A. Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. Proc. Natl Acad. Sci. USA 107, 20986–20991 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Foster, G. R. et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 141, 881–889.e1 (2011).
  Article CAS PubMed Google Scholar
• Silva, M. O. et al. Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3. J. Hepatol. 59, 31–37 (2013).
  Article CAS PubMed Google Scholar
• Maasoumy, B. & Manns, M. P. Optimal treatment with boceprevir for chronic HCV infection. Liver Int. 33, 14–22 (2013).
  Article CAS PubMed Google Scholar
• Jesudian, A. B. & Jacobson, I. M. Optimal treatment with telaprevir for chronic HCV infection. Liver Int. 33 (Suppl. 1), 3–13 (2013).
  Article CAS PubMed Google Scholar
• Vierling, J. M. et al. Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response. J. Hepatol. 60, 748–756 (2014).
  Article CAS PubMed Google Scholar
• Colombo, M. et al. Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C. Gut 63, 1150–1158 (2014).
  Article CAS PubMed Google Scholar
• Gordon, S. C. et al. Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET. J. Hepatol. 62, 286–293 (2015).
  Article CAS PubMed Google Scholar
• Poordad, F. et al. Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection–a randomized trial. Gastroenterology 145, 1035–1044.e5 (2013).
  Article CAS PubMed Google Scholar
• Hézode, C. et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J. Hepatol. 59, 434–441 (2013).
  Article PubMed Google Scholar
• Maasoumy, B. et al. Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease. Eur. J. Gastroenterol. Hepatol. 26, 836–845 (2014).
  Article CAS PubMed Google Scholar
• Sarrazin, C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J. Hepatol. 64, 486–504 (2016).
  Article PubMed Google Scholar
• Lemm, J. A. et al. Identification of hepatitis C virus NS5A inhibitors. J. Virol. 84, 482–491 (2010).
  Article CAS PubMed Google Scholar
• Gao, M. et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465, 96–100 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Lok, A. S. et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N. Engl. J. Med. 366, 216–224 (2012).
  Article CAS PubMed Google Scholar
• Manns, M. et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 384, 1597–1605 (2014).
  Article CAS PubMed Google Scholar
• Gower, E., Estes, C., Blach, S., Razavi-Shearer, K. & Razavi, H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J. Hepatol. 61, S45–S57 (2014).
  Article PubMed Google Scholar
• Wei, L. et al. A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin. J. Gastroenterol. Hepatol. 31, 1860–1867 (2016).
  Article CAS PubMed Google Scholar
• Abraham, G. M. & Spooner, L. M. Sofosbuvir in the treatment of chronic hepatitis C: new dog, new tricks. Clin. Infect. Dis. 59, 411–415 (2014).
  Article PubMed CAS Google Scholar
• Ludmerer, S. W. et al. Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay. Antimicrob. Agents Chemother. 49, 2059–2069 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Jacobson, I. M. et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N. Engl. J. Med. 368, 1867–1877 (2013).
  Article CAS PubMed Google Scholar
• Höner Zu Siederdissen, C. et al. Drug-drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohort. Clin. Infect. Dis. 62, 561–567 (2016).
  Article PubMed CAS Google Scholar
• Schulte, B. et al. Frequency of potential drug-drug interactions in the changing field of HCV therapy. Open Forum Infect. Dis. 7, ofaa040 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Lawitz, E. et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N. Engl. J. Med. 368, 1878–1887 (2013).
  Article CAS PubMed Google Scholar
• Gane, E. J. et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N. Engl. J. Med. 368, 34–44 (2013).
  Article CAS PubMed Google Scholar
• Manns, M. et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 384, 414–426 (2014).
  Article CAS PubMed Google Scholar
• Jacobson, I. M. et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 384, 403–413 (2014).
  Article CAS PubMed Google Scholar
• Reddy, K. R. et al. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. Lancet Infect. Dis. 15, 27–35 (2015).
  Article CAS PubMed Google Scholar
• Lawitz, E. et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 384, 1756–1765 (2014).
  Article CAS PubMed Google Scholar
• Sulkowski, M. S. et al. Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 Infection. Gastroenterology 150, 419–429 (2016).
  Article PubMed Google Scholar
• Kwo, P. et al. Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology 64, 370–380 (2016).
  Article CAS PubMed Google Scholar
• Lawitz, E. et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST-2). Hepatology 64, 360–369 (2016).
  Article CAS PubMed Google Scholar
• Hézode, C. et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut 64, 948–956 (2015).
  Article PubMed CAS Google Scholar
• Dore, G. J. et al. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection. Gastroenterology 148, 355–366.e1 (2015).
  Article CAS PubMed Google Scholar
• Jacobson, I. et al. Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1. World J. Gastroenterol. 22, 3418–3431 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Belperio, P. S., Shahoumian, T. A., Loomis, T. P., Mole, L. A. & Backus, L. I. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3. J. Hepatol. 70, 15–23 (2019).
  Article CAS PubMed Google Scholar
• Nelson, D. R. et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 61, 1127–1135 (2015).
  Article CAS PubMed Google Scholar
• Leroy, V. et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+). Hepatology 63, 1430–1441 (2016).
  Article CAS PubMed Google Scholar
• Sulkowski, M. S., Jacobson, I. M. & Nelson, D. R. Daclatasvir plus sofosbuvir for HCV infection. N. Engl. J. Med. 370, 1560–1561 (2014).
  Article PubMed CAS Google Scholar
• Ferenci, P. et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N. Engl. J. Med. 370, 1983–1992 (2014).
  Article PubMed CAS Google Scholar
• Poordad, F. et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N. Engl. J. Med. 370, 1973–1982 (2014).
  Article PubMed CAS Google Scholar
• Kowdley, K. V. et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N. Engl. J. Med. 370, 1879–1888 (2014).
  Article PubMed CAS Google Scholar
• Afdhal, N. et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N. Engl. J. Med. 370, 1483–1493 (2014).
  Article CAS PubMed Google Scholar
• Afdhal, N. et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N. Engl. J. Med. 370, 1889–1898 (2014).
  Article PubMed CAS Google Scholar
• Andreone, P. et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 147, 359–365.e1 (2014).
  Article CAS PubMed Google Scholar
• Dore, G. J. et al. Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: the MALACHITE-I/II trials. J. Hepatol. 64, 19–28 (2016).
  Article CAS PubMed Google Scholar
• Goodkin, D. A., Bieber, B., Gillespie, B., Robinson, B. M. & Jadoul, M. Hepatitis C infection is very rarely treated among hemodialysis patients. Am. J. Nephrol. 38, 405–412 (2013).
  Article CAS PubMed Google Scholar
• Kirby, B. J., Symonds, W. T., Kearney, B. P. & Mathias, A. A. Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir. Clin. Pharmacokinet. 54, 677–690 (2015).
  Article CAS PubMed Google Scholar
• Ohlendorf, V. & Maasoumy, B. Renal function in HCV therapy: just another thing to ignore? Liver Int. 40, 1018–1020 (2020).
  Article PubMed Google Scholar
• Desnoyer, A. et al. Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. J. Hepatol. 65, 40–47 (2016).
  Article CAS PubMed Google Scholar
• Pockros, P. J. et al. Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology 150, 1590–1598 (2016).
  Article CAS PubMed Google Scholar
• Flisiak, R. et al. Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study. Aliment. Pharmacol. Ther. 44, 946–956 (2016).
  Article CAS PubMed Google Scholar
• Saxena, V. et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int. 36, 807–816 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Lawitz, E. et al. Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study. Lancet Gastroenterol. Hepatol. 5, 918–926 (2020).
  Article PubMed Google Scholar
• Li, T., Qu, Y., Guo, Y., Wang, Y. & Wang, L. Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis. Liver Int. 37, 974–981 (2017).
  Article CAS PubMed Google Scholar
• Borgia, S. M. et al. Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. J. Hepatol. 71, 660–665 (2019).
  Article CAS PubMed Google Scholar
• Lawitz, E. et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous. Lancet 385, 1075–1086 (2015).
  Article CAS PubMed Google Scholar
• Kwo, P. et al. Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection. Gastroenterology 152, 164–175.e4 (2017).
  Article CAS PubMed Google Scholar
• Roth, D. et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 386, 1537–1545 (2015).
  Article CAS PubMed Google Scholar
• Krishnan, P. et al. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob. Agents Chemother. 59, 979–987 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Kati, W. et al. In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor. Antimicrob. Agents Chemother. 59, 1505–1511 (2015).
  Article PubMed PubMed Central Google Scholar
• Cheng, G. et al. In vitro antiviral activity and resistance profile characterization of the hepatitis C virus NS5A inhibitor ledipasvir. Antimicrob. Agents Chemother. 60, 1847–1853 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Feld, J. J. et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 Infection. N. Engl. J. Med. 373, 2599–2607 (2015).
  Article CAS PubMed Google Scholar
• Foster, G. R. et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 Infection. N. Engl. J. Med. 373, 2608–2617 (2015).
  Article CAS PubMed Google Scholar
• Esteban, R. et al. Efficacy of sofosbuvir and velpatasvir, with and without ribavirin, in patients with hepatitis C virus genotype 3 infection and cirrhosis. Gastroenterology 155, 1120–1127.e4 (2018).
  Article CAS PubMed Google Scholar
• Pawlotsky, J.-M. et al. EASL Recommendations on Treatment of Hepatitis C 2018. J. Hepatol. 69, 461–511 (2018).
  Article Google Scholar
• Stamm, L. M., Brainard, D. M. & McHutchison, J. G. Sofosbuvir/velpatasvir for patients with chronic genotype 3 HCV infection with compensated cirrhosis: response to EASL Recommendations on Treatment of Hepatitis C 2018. J. Hepatol. 70, 561–562 (2019).
  Article PubMed Google Scholar
• Puoti, M. et al. High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: an integrated analysis of HCV genotype 1-6 patients without cirrhosis. J. Hepatol. 69, 293–300 (2018).
  Article CAS PubMed Google Scholar
• Forns, X. et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect. Dis. 17, 1062–1068 (2017).
  Article CAS PubMed Google Scholar
• Zeuzem, S. et al. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N. Engl. J. Med. 378, 354–369 (2018).
  Article CAS PubMed Google Scholar
• Wyles, D. et al. Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: a partially randomized phase 3 clinical trial. Hepatology 67, 514–523 (2018).
  Article CAS PubMed Google Scholar
• Brown, R. S. et al. Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: the EXPEDITION-8 trial. J. Hepatol. 72, 441–449 (2020).
  Article CAS PubMed Google Scholar
• Forns, X. et al. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J. Hepatol. 63, 564–572 (2015).
  Article CAS PubMed Google Scholar
• Dietz, J. et al. Patterns of resistance-associated substitutions in patients with chronic HCV infection following treatment with direct-acting antivirals. Gastroenterology 154, 976–988.e4 (2018).
  Article PubMed Google Scholar
• Wyles, D. et al. Long-term persistence of HCV NS5A resistance-associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir. Antivir. Ther. 23, 229–238 (2017).
  Article Google Scholar
• Peiffer, K. H. et al. Interferon-free treatment choice according to baseline RASs leads to high SVR rates in HCV genotype 1 infected patients. J. Infect. Chemother. 24, 524–530 (2018).
  Article CAS PubMed Google Scholar
• Poordad, F. et al. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology 66, 389–397 (2017).
  Article CAS PubMed Google Scholar
• Poordad, F. et al. Glecaprevir/pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure. Hepatology 67, 1253–1260 (2018).
  Article CAS PubMed Google Scholar
• Wyles, D. et al. Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection. J. Hepatol. 70, 1019–1023 (2019).
  Article PubMed Google Scholar
• Papaluca, T. et al. Retreatment with elbasvir, grazoprevir, sofosbuvir ± ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapse. Liver Int. 39, 2285–2290 (2019).
  Article CAS PubMed Google Scholar
• Bourlière, M. et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N. Engl. J. Med. 376, 2134–2146 (2017).
  Article PubMed Google Scholar
• Vermehren, J. et al. Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: results from the German Hepatitis C-Registry (DHC-R). Z. Gastroenterol. 58, 841–846 (2020).
  Article CAS PubMed Google Scholar
• Martin, M. T., Patel, S., Kulik, L. & Chan, C. Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings. J. Hepatol. 75, 251–254 (2021).
  Article CAS PubMed Google Scholar
• Dietz, J. et al. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. J. Hepatol. 74, 801–810 (2021).
  Article CAS PubMed Google Scholar
• Bernhard, B. & Stickel, F. Successful fourth line treatment of a relapse patient with chronic hepatitis C virus infection genotype 3a using sofosbuvir, glecaprevir/pibrentasvir, and ribavirin: a case report. Z. Gastroenterol. 58, 451–455 (2020).
  Article CAS PubMed Google Scholar
• Fierer, D. S. & Wyles, D. L. Re-treatment of hepatitis c infection after multiple failures of direct-acting antiviral therapy. Open Forum Infect. Dis. 7, ofaa095 (2020).
  Article PubMed PubMed Central CAS Google Scholar
• Tergast, T. L. et al. Glecaprevir/pibrentasvir + sofosbuvir + ribavirin als reserveregime nach sofosbuvir + velpatasvir + voxilaprevir re-therapieversagen. Z. Gastroenterol. https://doi.org/10.1055/a-1649-8931 (2021).
  Article PubMed Google Scholar
• Gottwein, J. M. et al. Efficacy of NS5A inhibitors against hepatitis c virus genotypes 1-7 and escape variants. Gastroenterology 154, 1435–1448 (2018).
  Article CAS PubMed Google Scholar
• Curry, M. P. et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N. Engl. J. Med. 373, 2618–2628 (2015).
  Article CAS PubMed Google Scholar
• Charlton, M. et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 149, 649–659 (2015).
  Article CAS PubMed Google Scholar
• Manns, M. et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect. Dis. 16, 685–697 (2016).
  Article CAS PubMed Google Scholar
• Cheung, M. C. M. et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J. Hepatol. 65, 741–747 (2016).
  Article CAS PubMed Google Scholar
• Deterding, K. et al. Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies. Aliment. Pharmacol. Ther. 42, 889–901 (2015).
  Article CAS PubMed Google Scholar
• Mandorfer, M. et al. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J. Hepatol. 65, 692–699 (2016).
  Article PubMed Google Scholar
• El-Sherif, O. et al. Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection. Gastroenterology 154, 2111–2121.e8 (2018).
  Article CAS PubMed Google Scholar
• Younossi, Z. M. et al. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. Lancet Gastroenterol. Hepatol. 1, 122–132 (2016).
  Article PubMed Google Scholar
• Belli, L. S. et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study. J. Hepatol. 65, 524–531 (2016).
  Article PubMed Google Scholar
• Pascasio, J. M. et al. Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation. J. Hepatol. 67, 1168–1176 (2017).
  Article PubMed Google Scholar
• Foster, G. R. et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J. Hepatol. 64, 1224–1231 (2016).
  Article CAS PubMed Google Scholar
• Fernández Carrillo, C. et al. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: analysis of data from the Hepa-C registry. Hepatology 65, 1810–1822 (2017).
  Article PubMed CAS Google Scholar
• Sandmann, L. et al. Treatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver transplantation: real-life data from five German transplant centers. Eur. J. Gastroenterol. Hepatol. 31, 1049–1056 (2019).
  Article CAS PubMed Google Scholar
• Samur, S. et al. Cost effectiveness of pre- vs post-liver transplant hepatitis C treatment with direct-acting antivirals. Clin. Gastroenterol. Hepatol. 16, 115–122.e10 (2018).
  Article PubMed Google Scholar
• Kim, W. R. et al. OPTN/SRTR 2012 annual data report: liver. Am. J. Transpl. 14 (Suppl. 1), 69–96 (2014).
  Article Google Scholar
• Blasco, A. et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 43, 492–499 (2006).
  Article PubMed Google Scholar
• Kwo, P. Y. et al. An interferon-free antiviral regimen for HCV after liver transplantation. N. Engl. J. Med. 371, 2375–2382 (2014).
  Article PubMed CAS Google Scholar
• Reau, N. et al. Glecaprevir/pibrentasvir treatment in liver or kidney transplant patients with hepatitis C virus infection. Hepatology 68, 1298–1307 (2018).
  Article CAS PubMed Google Scholar
• Agarwal, K. et al. Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients. J. Hepatol. 69, 603–607 (2018).
  Article CAS PubMed Google Scholar
• Kiser, J. J., Burton, J. R., Anderson, P. L. & Everson, G. T. Review and management of drug interactions with boceprevir and telaprevir. Hepatology 55, 1620–1628 (2012).
  Article CAS PubMed Google Scholar
• Maasoumy, B. et al. The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C. Aliment. Pharmacol. Ther. 38, 1365–1372 (2013).
  Article CAS PubMed Google Scholar
• Crespo, G. et al. The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition. J. Hepatol. 69, 11–17 (2018).
  Article CAS PubMed Google Scholar
• Cotter, T. G. et al. Improved graft survival after liver transplantation for recipients with hepatitis C virus in the direct-acting antiviral era. Liver Transpl. 25, 598–609 (2019).
  Article PubMed Google Scholar
• Hutchinson, S. J. et al. Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: a national record-linkage study. Gut 69, 2223–2231 (2020).
  Article PubMed Google Scholar
• Rodríguez-Tajes, S. et al. Hepatitis C-related cirrhosis will be a marginal cause of hospital admissions by 2025. J. Hepatol. 73, 1360–1367 (2020).
  Article PubMed CAS Google Scholar
• Razavi, H., Sanchez Gonzalez, Y., Yuen, C. & Cornberg, M. Global timing of hepatitis C virus elimination in high-income countries. Liver Int. 40, 522–529 (2020).
  Article PubMed Google Scholar
• Blach, S. et al. Impact of COVID-19 on global HCV elimination efforts. J. Hepatol. 74, 31–36 (2021).
  Article CAS PubMed Google Scholar
• Wedemeyer, H. et al. Strategies to manage hepatitis C virus (HCV) disease burden. J. Viral Hepat. 21 (Suppl. 1), 60–89 (2014).
  Article PubMed Google Scholar
• Razavi, H. et al. The present and future disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm. J. Viral Hepat. 21 (Suppl. 1), 34–59 (2014).
  Article PubMed Google Scholar
• Averhoff, F. et al. Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia. J. Hepatol. 72, 680–687 (2020).
  Article CAS PubMed Google Scholar
• Nasrullah, M., Sergeenko, D., Gamkrelidze, A. & Averhoff, F. HCV elimination — lessons learned from a small Eurasian country, Georgia. Nat. Rev. Gastroenterol. Hepatol. 14, 447–448 (2017).
  Article PubMed Google Scholar
• Waked, I. et al. Screening and treatment program to eliminate hepatitis C in Egypt. N. Engl. J. Med. 382, 1166–1174 (2020).
  Article PubMed Google Scholar
• van de Ven, N. et al. Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus. Hepatology 61, 1174–1182 (2015).
  Article PubMed CAS Google Scholar
• Hill, A., Khoo, S., Fortunak, J., Simmons, B. & Ford, N. Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clin. Infect. Dis. 58, 928–936 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Dhiman, R. K. et al. Decentralized care with generic direct-acting antivirals in the management of chronic hepatitis C in a public health care setting. J. Hepatol. 71, 1076–1085 (2019).
  Article PubMed Google Scholar
• Scott, N. et al. Modelling the elimination of hepatitis C as a public health threat in Iceland: a goal attainable by 2020. J. Hepatol. 68, 932–939 (2018).
  Article PubMed Google Scholar
• Heffernan, A., Cooke, G. S., Nayagam, S., Thursz, M. & Hallett, T. B. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. Lancet 393, 1319–1329 (2019).
  Article PubMed PubMed Central Google Scholar
• Degenhardt, L. et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob. Heal. 5, e1192–e1207 (2017).
  Article Google Scholar
• Dore, G. J. et al. Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial. Ann. Intern. Med. 165, 625–634 (2016).
  Article PubMed Google Scholar
• Christensen, S. et al. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: still a concern in clinical practice. Addiction 113, 868–882 (2018).
  Article PubMed Google Scholar
• Grebely, J. et al. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. Lancet Gastroenterol. Hepatol. 3, 153–161 (2018).
  Article PubMed Google Scholar
• Christensen, S. et al. Alcohol and cannabis consumption does not diminish cure rates in a real-world cohort of chronic hepatitis C virus infected patients on opioid substitution therapy-data from the german hepatitis C-registry (DHC-R). Subst. Abus. 13, 1178221819835847 (2019).
  Google Scholar
• Talal, A. H. et al. Integrated, co-located, telemedicine-based treatment approaches for hepatitis C virus management in opioid use disorder patients on methadone. Clin. Infect. Dis. 69, 323–331 (2019).
  Article PubMed Google Scholar
• Janssen, H. L. et al. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 368, 1685–1694 (2013).
  Article CAS PubMed Google Scholar
• Ingiliz, P. et al. Reinfection with the hepatitis C virus in men who have sex with men after successful treatment with direct-acting antivirals in germany: current incidence rates, compared with rates during the interferon era. Clin. Infect. Dis. 71, 1248–1254 (2020).
  Article CAS PubMed Google Scholar
• Ingiliz, P. et al. HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe. J. Hepatol. 66, 282–287 (2017).
  Article PubMed Google Scholar
• Boerekamps, A. et al. High treatment uptake in human immunodeficiency virus/hepatitis C virus-coinfected patients after unrestricted access to direct-acting antivirals in the Netherlands. Clin. Infect. Dis. 66, 1352–1359 (2018).
  Article PubMed Google Scholar
• Deterding, K. et al. Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. Lancet Infect. Dis. 13, 497–506 (2013).
  Article PubMed Google Scholar
• Bethea, E. D., Chen, Q., Hur, C., Chung, R. T. & Chhatwal, J. Should we treat acute hepatitis C? A decision and cost-effectiveness analysis. Hepatology 67, 837–846 (2018).
  Article PubMed Google Scholar
• Deterding, K. et al. Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. Lancet Infect. Dis. 17, 215–222 (2017).
  Article CAS PubMed Google Scholar
• Boerekamps, A. et al. Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial. Lancet Gastroenterol. Hepatol. 4, 269–277 (2019).
  Article PubMed Google Scholar
• Riddell, J., Amico, K. R. & Mayer, K. H. HIV preexposure prophylaxis: a review. JAMA 319, 1261–1268 (2018).
  Article PubMed Google Scholar
• Page, K. et al. Randomized trial of a vaccine regimen to prevent chronic HCV infection. N. Engl. J. Med. 384, 541–549 (2021).
  Article CAS PubMed PubMed Central Google Scholar
• Sofia, M. J. et al. Discovery of a β-d-2’-deoxy-2’-α-fluoro-2’-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J. Med. Chem. 53, 7202–7218 (2010).
  Article CAS PubMed Google Scholar
• Curry, M. P. et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 148, 100–110 (2014).
  Article PubMed CAS Google Scholar
• Tobler, L. H. & Busch, M. P. History of posttransfusion hepatitis. Clin. Chem. 43, 1487–1493 (1997).
  Article CAS PubMed Google Scholar
• Heathcote, E. J. et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N. Engl. J. Med. 343, 1673–1680 (2000).
  Article CAS PubMed Google Scholar
• Buti, M. et al. Telaprevir twice daily is noninferior to telaprevir every 8 h for patients with chronic hepatitis C. Gastroenterology 146, 744–753.e3 (2014).
  Article CAS PubMed Google Scholar
• Dechanont, S., Maphanta, S., Butthum, B. & Kongkaew, C. Hospital admissions/visits associated with drug-drug interactions: a systematic review and meta-analysis. Pharmacoepidemiol. Drug Saf. 23, 489–497 (2014).
  Article PubMed Google Scholar
• Werner, C. R. et al. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data. Liver Transpl. 18, 1464–1470 (2012).
  Article PubMed Google Scholar
• Kanter, C. T., Luin, M., Solas, C., Burger, D. M. & Vrolijk, J. M. Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin. Ann. Hepatol. 13, 452–455 (2014).
  Article PubMed Google Scholar
• Vermehren, J. et al. Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection. J. Hepatol. 60, 913–919 (2014).
  Article CAS PubMed Google Scholar
• Maasoumy, B. et al. Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir. Aliment. Pharmacol. Ther. 39, 85–92 (2014).
  Article CAS PubMed Google Scholar
• Maasoumy, B. et al. Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis. PLoS ONE 9, e110857 (2014).
  Article PubMed PubMed Central CAS Google Scholar
• Maasoumy, B. & Vermehren, J. Diagnostics in hepatitis C: the end of response-guided therapy? J. Hepatol. 65, S67–S81 (2016).
  Article PubMed Google Scholar
• Vermehren, J. et al. Applicability of Hepatitis C virus RNA viral load thresholds for 8-week treatments in patients with chronic hepatitis C virus genotype 1 infection. Clin. Infect. Dis. 62, 1228–1234 (2016).
  Article CAS PubMed Google Scholar
• Terrault, N. A. et al. Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained virologic response. Gastroenterology 151, 1131–1140.e5 (2016).
  Article CAS PubMed Google Scholar
• Buggisch, P. et al. Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C. J. Hepatol. 68, 663–671 (2018).
  Article CAS PubMed Google Scholar
• Ingiliz, P. et al. Sofosbuvir and ledipasvir for 8 weeks for the treatment of chronic hepatitis C Virus (HCV) infection in HCV-monoinfected and HIV-HCV-coinfected individuals: results from the German hepatitis C cohort (GECCO-01). Clin. Infect. Dis. 63, 1320–1324 (2016).
  Article CAS PubMed Google Scholar
• Maasoumy, B. et al. Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients. Liver Int. 38, 1906–1910 (2018).
  Article CAS PubMed Google Scholar
• Halleck, F. et al. Transplanting HCV-infected kidneys into uninfected recipients. N. Engl. J. Med. 377, 1103–1104 (2017).
  Article PubMed Google Scholar
• Colombo, M. et al. Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial. Ann. Intern. Med. 166, 109–117 (2017).
  Article PubMed Google Scholar
• Schlendorf, K. H. et al. Early outcomes using hepatitis C-positive donors for cardiac transplantation in the era of effective direct-acting anti-viral therapies. J. Hear. Lung Transpl. 37, 763–769 (2018).
  Article Google Scholar
• Nangia, G., Borges, K. & Reddy, K. R. Use of HCV-infected organs in solid organ transplantation: an ethical challenge but plausible option. J. Viral Hepat. 26, 1362–1371 (2019).
  Article PubMed Google Scholar
• Fishman, J. A. & Forns, X. HCV-positive donor organs in solid organ transplantation: ‘Mind the Gap!’. Am. J. Transpl. 17, 2755–2756 (2017).
  Article CAS Google Scholar
• Samuel, D. HCV-positive organ transplants in HCV-negative recipients. Lancet Gastroenterol. Hepatol. 4, 745–747 (2019).
  Article PubMed Google Scholar
• Gupta, G., Zhang, Y., Carroll, N. V. & Sterling, R. K. Cost-effectiveness of hepatitis C-positive donor kidney transplantation for hepatitis C-negative recipients with concomitant direct-acting antiviral therapy. Am. J. Transpl. 18, 2496–2505 (2018).
  Article Google Scholar
• Kadatz, M., Klarenbach, S., Gill, J. & Gill, J. S. Cost-effectiveness of using kidneys from hepatitis C nucleic acid test-positive donors for transplantation in hepatitis C-negative recipients. Am. J. Transpl. 18, 2457–2464 (2018).
  Article Google Scholar
• Thuluvath, P. J. et al. Use of HCV-positive livers in HCV-negative recipients. Am. J. Gastroenterol. 115, 1045–1054 (2020).
  Article PubMed Google Scholar
• Kwong, A. J. et al. Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors. Am. J. Transpl. 19, 1380–1387 (2019).
  Article CAS Google Scholar
• Cotter, T. G. et al. Increasing utilization and excellent initial outcomes following liver transplant of hepatitis C virus (HCV)-viremic donors into HCV-negative recipients: outcomes following liver transplant of HCV-viremic donors. Hepatology 69, 2381–2395 (2019).
  CAS PubMed Google Scholar
• La Hoz, R. M., Sandıkçı, B., Ariyamuthu, V. K. & Tanriover, B. Short-term outcomes of deceased donor renal transplants of HCV uninfected recipients from HCV seropositive nonviremic donors and viremic donors in the era of direct-acting antivirals. Am. J. Transpl. 19, 3058–3070 (2019).
  Article CAS Google Scholar
• Wang, J. H. et al. OPTN/SRTR 2018 Annual Data Report: Hepatitis C. Am. J. Transpl. 20 (Suppl.), 542–568 (2020).
  Article Google Scholar
• Chhatwal, J. et al. Transplanting hepatitis C virus-positive livers into hepatitis C virus-negative patients with preemptive antiviral treatment: a modeling study. Hepatology 67, 2085–2095 (2018).
  Article CAS PubMed Google Scholar
• Bethea, E. D. et al. Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study. Lancet Gastroenterol. Hepatol. 4, 771–780 (2019).
  Article PubMed Google Scholar
• Cypel, M. et al. Prevention of viral transmission during lung transplantation with hepatitis C-viraemic donors: an open-label, single-centre, pilot trial. Lancet Respir. Med. 8, 192–201 (2020).
  Article CAS PubMed Google Scholar
• Belli, L. S. et al. Impact of DAAs on liver transplantation: major effects on the evolution of indications and results. An ELITA study based on the ELTR registry. J. Hepatol. 69, 810–817 (2018).
  Article CAS PubMed Google Scholar